Article
Pharmacology & Pharmacy
Xiaohui Zeng, Qiao Liu, Chongqing Tan, Xiaomin Wan, Yunhua Wang, Xiaowei Ma
Summary: This study assessed the cost effectiveness of radium-223 dichloride for Chinese patients with mCRPC. The results suggest that radium-223 may not be cost effective for patients with bone mCRPC from the perspective of the Chinese health system.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Mari I. Suominen, Matias Knuuttila, Christoph A. Schatz, Andreas Schlicker, Jukka Vaaraniemi, Birgitta Sjoholm, Esa Alhoniemi, Bernard Haendler, Dominik Mumberg, Sanna-Maria Kakonen, Arne Scholz
Summary: In this study, the antitumor efficacy of radium-223, enzalutamide, and their combination was evaluated in a model of prostate cancer metastasis to bone. The combination treatment showed synergistic efficacy and enhanced antitumor effect in vitro and in vivo without compromising healthy bone integrity. These results support the ongoing phase 3 trial of radium-223 and enzalutamide combination therapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Multidisciplinary Sciences
Ana Maria Garcia Vicente, Mariano Amo-Salas, Javier Cassinello Espinosa, Roberto Gomez Diaz, Angel Soriano Castrejon
Summary: The ChoPET-Rad study involving 82 patients with CRPC-BM demonstrated that end-treatment FCH PET/CT was associated with PFS and OS, while interim FCH PET/CT was a good predictor of biochemical progression. Therapeutic failure and progression in interim BS or FCH PET/CT were adverse factors for OS.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Benjamin L. Maughan, Adam Kessel, Taylor Ryan McFarland, Nicolas Sayegh, Roberto Nussenzveig, Andrew W. Hahn, John M. Hoffman, Kathyrn Morton, Deepika Sirohi, Manish Kohli, Umang Swami, Kenneth Boucher, Benjamin Haaland, Neeraj Agarwal
Summary: The combination of radium-223 with enzalutamide was confirmed to be safe and associated with promising efficacy in the long-term treatment of metastatic castration-resistant prostate cancer patients. These results support the ongoing phase III PEACE III trial in this setting.
Article
Oncology
Raymond S. McDermott, John Greene, John McCaffrey, Imelda Parker, Sylva Helanova, Anne-Marie Baird, Ausra Teiserskiene, Marvin Lim, Helen Matthews, Olwyn Deignan, John Feeney, Pierre G. Thirion, Stephen P. Finn, Paul J. Kelly
Summary: The combination of radium-223 and enzalutamide was found to be tolerable in men with progressive mCRPC and bone metastases, with the majority of patients completing the combination treatment. Although bone fractures during the combination period were uncommon, a higher incidence of fractures was identified in patients after completing combination treatment. Therefore, bone health agents should be administered and bone health should be closely monitored following treatment with radium-223 and enzalutamide.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2021)
Article
Urology & Nephrology
Tiziana Angusti, Rosario F. Di Stefano, Antonella Parente, Maristella Bungaro, Fabio Turco, Alessandro Samuelly, Chiara Pisano, Giorgio Scagliotti, Massimo Di Maio, Marcello Tucci, Consuelo Buttigliero
Summary: The study aims to identify baseline prognostic factors in metastatic castration resistant prostate cancer patients treated with radium-223. The results showed that LN involvement, strong opioids use, baseline ALP, LDH, and PLR levels were significantly associated with outcome in these patients.
MINERVA UROLOGY AND NEPHROLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Maarten J. van der Doelen, Agnes Stockhaus, Yuanjun Ma, Niven Mehra, Jeffrey Yachnin, Winald R. Gerritsen, Sten Nilsson, Inge M. van Oort, Anders Ullen
Summary: The study showed that early treatment-induced changes in ALP after one radium-223 injection were associated with overall survival in metastatic CRPC patients.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Geriatrics & Gerontology
Viviana Frantellizzi, Fabio Monari, Manlio Mascia, Renato Costa, Giuseppe Rubini, Angela Spanu, Alessio Farcomeni, Elisa Lodi Rizzini, Luca Cindolo, Alessandra Murabito, Valentina Lavelli, Susanna Nuvoli, Laura Cosma, Valeria Dionisi, Anna Giulia Nappi, Marco Andreola, Giuseppe De Vincentis
Summary: The study found that in mCRPC patients, there was no significant difference in OS between younger and older patients treated with Radium-223, and age did not have a significant impact on OS. The toxic effects of Radium-223 were similar in the two groups.
AGING CLINICAL AND EXPERIMENTAL RESEARCH
(2021)
Article
Oncology
Joroen H. A. Creemers, Maarten J. van der Doelen, Sandra van Wilpe, Rick Hermsen, Tjitske Duiveman-de Boer, Diederik M. Somford, Marcel J. R. Janssen, J. P. Michiel Sedelaar, Niven Mehra, Johannes Textor, Harm Westdorp
Summary: Immune cell subsets in mCRPC patients changed during radium-223 therapy, with decreased absolute lymphocyte counts and increased expression of checkpoint molecules in T cells. The immunosuppressive subsets, including regulatory T cells and monocytic MDSCs, also increased throughout treatment. Further research is needed to explore the potential immunological consequences of these changes.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Ahmad Shariftabrizi, Shalin Kothari, Saby George, Kristopher Attwood, Ellis Levine, Dominick Lamonica
Summary: This study identifies bone scintigraphy as a potentially important biomarker for selecting prostate cancer patients with bone metastasis who will benefit most from Ra-223 treatment. Patients with lower baseline Bone Scan Index (BSI) levels are more likely to have better outcomes following treatment, while those with higher BSI levels have poorer survival rates.
Article
Oncology
Kevin Kaulanjan, Johanna Dahan, Cedric Charrois-Durand, Fred Saad, Laurent Brureau, Guila Delouya, Daniel Taussky, Edouard Auclin
Summary: This study analyzed the prognostic value of the neutrophil to lymphocyte ratio (NLR) in metastatic prostate cancer patients. The results showed that a low NLR at baseline and at 12 weeks of treatment was associated with longer overall survival in patients treated with Ra-223 but not in patients treated with Docetaxel. Further validation in larger prospective cohorts is needed.
Article
Oncology
Maira Khan, Shruti Parshad, Mahdi F. Naimi, Amanjot K. Sidhu, Frank Lyons, Michael R. Hardisty, Cari M. Whyne, Martin Smoragiewicz, Cameron M. Phillips, Juan Briones, Urban Emmenegger
Summary: There are complex interactions between bone and skeletal muscle. However, the prevention and treatment of osteosarcopenia in men with metastatic castration-resistant prostate cancer focuses predominantly on bone health. In a study involving 52 patients, it was found that bone-targeted Radium-223 therapy does not accelerate sarcopenia, but baseline sarcopenia is associated with poor survival in such patients.
CLINICAL GENITOURINARY CANCER
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Kazuhiro Kitajima, Masataka Igeta, Junpei Kuyama, Takashi Kawahara, Tsuyoshi Suga, Tomoaki Otani, Shigeyasu Sugawara, Yumiko Kono, Yukihisa Tamaki, Ayumi Seko-Nitta, Yoshinobu Ishiwata, Kimiteru Ito, Akira Toriihara, Shiro Watanabe, Makoto Hosono, Hideaki Miyake, Shingo Yamamoto, Mitsuhiro Narita, Takashi Daimon, Koichiro Yamakado
Summary: A novel nomogram for determining the suitability of radium-223 dichloride (Ra-223) treatment for metastatic castration-resistant prostate cancer (mCRPC) patients was developed. The nomogram showed good discrimination and could assist clinicians in making treatment decisions.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Oncology
Hao Xiang Chen, Li-Hsien Tsai, Chao-Hsiang Chang, Hsi-Chin Wu, Ching-Chan Lin, Che-Hung Lin, Chin-Chung Yeh, Chi-Rei Yang, Chi-Shun Lien, Yi-Huei Chang, Ji-An Liang, Guan-Heng Chen, Po-Jen Hsiao, Po-Fan Hsieh, Chi-Ping Huang
Summary: This study evaluated the efficacy and safety of radium-223 in patients with mCRPC who had received prior treatment with enzalutamide or abiraterone. The results showed that patients who received enzalutamide prior to radium-223 had a significantly longer overall survival compared to those who received abiraterone. In addition, the number of doses of radium-223 received was also associated with overall survival. This study suggests that enzalutamide prior to radium-223 administration may lead to better outcomes in mCRPC patients.
Article
Medicine, General & Internal
Amanjot Sidhu, Nabeeha Khan, Cameron Phillips, Juan Briones, Anil Kapoor, Pawel Zalewski, Neil E. Fleshner, Edward Chow, Urban Emmenegger
Summary: In this study, we found that approximately 20% of patients with metastatic castration-resistant prostate cancer (mCRPC) experience PSA flares induced by Ra223 treatment, and these flares are not closely associated with patient outcomes. Although only a few patients had PSA decreases greater than 30% after the flare, the overall survival was comparable to patients with PSA responses or non-responses.
JOURNAL OF CLINICAL MEDICINE
(2023)